CLINICAL TRIALS PROFILE FOR CONJUGATED ESTROGENS

All Clinical Trials for CONJUGATED ESTROGENS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000419 ↗	Safety of Estrogens in Lupus: Hormone Replacement Therapy	Terminated	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1996-04-01	Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000419 ↗	Safety of Estrogens in Lupus: Hormone Replacement Therapy	Terminated	Office of Research on Women's Health (ORWH)	Phase 3	1996-04-01	Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000419 ↗	Safety of Estrogens in Lupus: Hormone Replacement Therapy	Terminated	New York University School of Medicine	Phase 3	1996-04-01	Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000419 ↗	Safety of Estrogens in Lupus: Hormone Replacement Therapy	Terminated	NYU Langone Health	Phase 3	1996-04-01	Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000430 ↗	Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis	Terminated	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1999-10-01	Osteoporosis, a condition in which bones are fragile and break easily, is a major health problem for postmenopausal women. Research studies have shown that both estrogen/progestin replacement therapy (hormone replacement therapy, or HRT) and alendronate are effective in preventing and treating osteoporosis. However, because these drugs work in somewhat different ways, a combination of the two drugs might protect women from osteoporosis better than either drug alone. In this study we will test whether HRT and alendronate given together for 3.5 years to postmenopausal women with low bone mass will have a greater effect on bone than either HRT or alendronate given alone. We will also give every participant in this study calcium and vitamin D supplements.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Clinical Trial Conditions for CONJUGATED ESTROGENS

Condition Name

Condition Name for CONJUGATED ESTROGENS
Intervention	Trials
Menopause	14
Osteoporosis	10
Postmenopause	8
Breast Cancer	4

Condition MeSH

Condition MeSH for CONJUGATED ESTROGENS
Intervention	Trials
Osteoporosis	10
Breast Neoplasms	7
Hot Flashes	4
Atrophy	3

Clinical Trial Locations for CONJUGATED ESTROGENS

Trials by Country

Trials by Country for CONJUGATED ESTROGENS
Location	Trials
United States	360
Mexico	3
Colombia	3
Australia	3
Brazil	3

Trials by US State

Trials by US State for CONJUGATED ESTROGENS
Location	Trials
California	19
Pennsylvania	18
Florida	17
North Carolina	14
Texas	13

Clinical Trial Progress for CONJUGATED ESTROGENS

Clinical Trial Phase

Clinical Trial Phase for CONJUGATED ESTROGENS
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	19
Phase 2	10

Clinical Trial Status

Clinical Trial Status for CONJUGATED ESTROGENS
Clinical Trial Phase	Trials
Completed	42
Terminated	7
Recruiting	5

Clinical Trial Sponsors for CONJUGATED ESTROGENS

Sponsor Name

Sponsor Name for CONJUGATED ESTROGENS
Sponsor	Trials
Wyeth is now a wholly owned subsidiary of Pfizer	13
Pfizer	10
National Cancer Institute (NCI)	7

Sponsor Type

Sponsor Type for CONJUGATED ESTROGENS
Sponsor	Trials
Other	80
Industry	29
NIH	21

Conjugated Estrogens: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: March 7, 2026

Are Current Clinical Trials Exploring New Indications or Formulations?

As of 2023, conjugated estrogens (CE) primarily target menopausal symptom relief and hormone replacement therapy (HRT). The focus of ongoing clinical trials has shifted toward understanding safety profiles, especially regarding cardiovascular risk, breast cancer, and cognitive effects.

Key current trials include:

• Efficacy in menopausal symptom management with improved formulations for reduced side effects (NCT04863287).
• Evaluation of cardiovascular safety in older women (NCT04592401).
• Potential neuroprotective effects in postmenopausal women at risk of cognitive decline (NCT05130009).

Few trials explore new indications beyond traditional HRT. There is limited investigation into other potential uses, such as osteoporosis or certain cancers, due to regulatory and market constraints.

How Are Clinical Trial Outcomes Shaping Market Dynamics?

Clinical trial outcomes heavily influence market acceptance. Positive safety and efficacy data bolster patent protections, support label expansions, and attract partnerships.

• Recent Phase III data reinforce CE's efficacy in reducing menopausal vasomotor symptoms.
• Ongoing studies aim to demonstrate an improved safety profile relative to bioidentical estrogen formulations, potentially broadening market appeal.
• Challenges include safety concerns about breast cancer risk and cardiovascular effects, which remain central in ongoing trials.

What Is the Current Market Size and Its Drivers?

The global estrogen therapy market, dominated by CE products, was valued at approximately $2.8 billion in 2022. It is projected to reach $4.2 billion by 2028, with a compound annual growth rate (CAGR) of roughly 6.2%.

Market drivers:

• Aging female population increasing menopause-related health demands.
• Growing awareness of hormone replacement options.
• Development of new formulations with improved safety profiles.

Market constraints:

• Safety concerns, particularly the increased breast cancer risk associated with estrogen therapy.
• Stringent regulatory environment demanding comprehensive safety data.
• Competition from bioidentical and plant-based estrogen products.

How Do Patent and Regulatory Policies Affect Market Potential?

Patent exclusivity remains critical; most CE formulations are protected until at least 2030. Patent expirations could open generic competition, exerting price pressure.

Regulatory changes, especially in the U.S. and EU, focus on risk-benefit profiles, pressuring manufacturers to innovate safer formulations. The U.S. Food and Drug Administration (FDA) emphasizes post-market surveillance. The European Medicines Agency (EMA) imposes strict labeling and safety reporting standards.

What Are Future Market Growth Opportunities?

Potential growth areas:

• Extended indications: Combining CE with progestins for contraception or osteoporosis management.
• Novel formulations: Transdermal patches, gels, or implants offering improved safety and compliance.
• Personalized therapy: Genetic markers predicting therapy response, reducing adverse effects.

Developers investing in formulations with enhanced safety profiles could capture larger market shares, especially as safety concerns remain central.

How Does Competition Shape the Market Landscape?

Major competitors include Pfizer (Premarin), Novo Nordisk, and generic producers. Patent expirations have led to increased generic entries, reducing prices and margins.

Emerging bisphosphonate and selective estrogen receptor modulators (SERMs) pose competition by offering alternative osteoporosis treatments with better safety profiles. The growing acceptance of non-hormonal options further constrains CE's growth potential.

Summary of Key Market Data

Parameter	Details
2022 Market Valuation	$2.8 billion
2028 Projected Market Size	$4.2 billion
CAGR	6.2%
Patent Expiry Dates	Most patents expire by 2030
Major Players	Pfizer, Novo Nordisk, Teva, Mylan
Key Regulatory Agencies	FDA (U.S.), EMA (EU)

Key Takeaways

• Clinical trials mainly focus on safety and efficacy in menopausal populations.
• Market growth driven by aging demographics and demand for safer formulations.
• Patent expirations and regulatory pressures influence innovation and competitive dynamics.
• Future opportunities involve extended indications, novel delivery systems, and personalized therapy.
• Competition from generic products and non-hormonal drugs presents challenges to sustained growth.

FAQs

1. What are the main safety concerns associated with conjugated estrogens?
Primarily breast cancer risk, cardiovascular events, and thromboembolism.

2. Are there new formulation options for conjugated estrogens?
Yes, transdermal patches, gels, and implants are under development to improve safety and compliance.

3. How does patent expiry affect the conjugated estrogens market?
Patent expiry around 2030 could lead to increased generic competition, reducing prices and profit margins.

4. Can conjugated estrogens be used for indications other than menopause-related symptoms?
Currently limited; research is ongoing for osteoporosis and neuroprotective effects, but these are not yet established indications.

5. What regulatory factors could influence future CE market growth?
Regulations emphasizing safety assessments and post-marketing surveillance can either restrict or enable market expansion depending on outcomes.

---

References

[1] MarketsandMarkets. (2023). Esterogen Market by Type, Formulation, Application, and Region. Retrieved from https://www.marketsandmarkets.com.

[2] U.S. National Library of Medicine. (2023). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov.

[3] Mordente, A., et al. (2022). Estrogen Therapy in Postmenopause: New Perspectives and Challenges. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.856508

[4] European Medicines Agency. (2023). Hormone Replacement Therapy Guidelines. https://www.ema.europa.eu